Exact Sciences (EXAS) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Exact Sciences Announces Second Quarter 2022 Results
August 2, 2022 4:07 PM EDTSecond quarter highlights
Total second quarter revenue of $522 million, including Screening revenue of $354 million, Precision Oncology revenue of $154 million, and COVID-19 testing revenue of $14 millionTotal second quarter revenue, excluding COVID-19 testing, increased 26 percent compared to the second quarter of 2021, including 34 percent increase in Screening revenue and 12 percent increase in Precision Oncology revenueScreening revenue growth driven by improved sales team productivity, Cologuard marketing partnership with Katie Couric, Cologuard rescreens, and Cologuard use in 45-49 age groupMADISON, Wis., Aug. 2, 2022... More
